• Something wrong with this record ?

The effect of levetiracetam on rat bone mineral density, bone structure and biochemical markers of bone metabolism

I. Karesova, J. Simko, S. Fekete, E. Zimcikova, J. Malakova, H. Zivna, L. Pavlikova, V. Palicka,

. 2018 ; 824 (-) : 115-119. [pub] 20180208

Language English Country Netherlands

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc18033323

Some data suggest that exposure to levetiracetam (LEV) might be associated with a risk for bone health in the model of orchidectomized rats. The aim of this study was to investigate if there is any significant risk of LEV for bone health in the model of gonadally intact animals. Wistar rats were divided into a control group and a test group, 8 rats in each group. The control rats received standard laboratory diet (SLD) while rats in the test group were fed SLD enriched with LEV for 12 weeks. Dual energy X-ray absorptiometry was used to measure BMD of the whole body, femur and lumbar vertebrae. The concentrations of bone markers were examined in bone homogenate. Both femurs and tibiae were used for biomechanical testing. We found in the LEV group significantly decreased absolute and relative values of adipose tissue, higher whole-body BMD, higher right tibia cortical thickness, and a significantly increased concentration of Bone Alkaline Phosphatase (BALP) and cross-linked C-telopeptide of type I collagen (CTX-I) compared with the control group. The results suggest that the long-term administration of LEV in the model of gonadally intact rats does not have a negative effect on bone. Significant increase in BMD and cortical thickness of the right tibia may indicate even a positive influence on the properties of bone. Further studies will be necessary in animals and humans to confirm these findings.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033323
003      
CZ-PrNML
005      
20181024152314.0
007      
ta
008      
181008s2018 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejphar.2018.02.010 $2 doi
035    __
$a (PubMed)29428468
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Karesova, Iva $u Institute of Clinical Biochemistry and Diagnostics, Charles University in Prague, Faculty of Medicine and University Hospital, Hradec Kralove, Czech Republic. Electronic address: karesova.iva@gmail.com.
245    14
$a The effect of levetiracetam on rat bone mineral density, bone structure and biochemical markers of bone metabolism / $c I. Karesova, J. Simko, S. Fekete, E. Zimcikova, J. Malakova, H. Zivna, L. Pavlikova, V. Palicka,
520    9_
$a Some data suggest that exposure to levetiracetam (LEV) might be associated with a risk for bone health in the model of orchidectomized rats. The aim of this study was to investigate if there is any significant risk of LEV for bone health in the model of gonadally intact animals. Wistar rats were divided into a control group and a test group, 8 rats in each group. The control rats received standard laboratory diet (SLD) while rats in the test group were fed SLD enriched with LEV for 12 weeks. Dual energy X-ray absorptiometry was used to measure BMD of the whole body, femur and lumbar vertebrae. The concentrations of bone markers were examined in bone homogenate. Both femurs and tibiae were used for biomechanical testing. We found in the LEV group significantly decreased absolute and relative values of adipose tissue, higher whole-body BMD, higher right tibia cortical thickness, and a significantly increased concentration of Bone Alkaline Phosphatase (BALP) and cross-linked C-telopeptide of type I collagen (CTX-I) compared with the control group. The results suggest that the long-term administration of LEV in the model of gonadally intact rats does not have a negative effect on bone. Significant increase in BMD and cortical thickness of the right tibia may indicate even a positive influence on the properties of bone. Further studies will be necessary in animals and humans to confirm these findings.
650    _2
$a zvířata $7 D000818
650    _2
$a biologické markery $x metabolismus $7 D015415
650    _2
$a biomechanika $x účinky léků $7 D001696
650    _2
$a tělesná hmotnost $x účinky léků $7 D001835
650    _2
$a kostní denzita $x účinky léků $7 D015519
650    _2
$a femur $x anatomie a histologie $x účinky léků $x metabolismus $x fyziologie $7 D005269
650    _2
$a bederní obratle $x anatomie a histologie $x účinky léků $x metabolismus $x fyziologie $7 D008159
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a velikost orgánu $x účinky léků $7 D009929
650    _2
$a piracetam $x analogy a deriváty $x farmakologie $7 D010889
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
655    _2
$a časopisecké články $7 D016428
700    1_
$a Simko, Julius $u Department of Neurology, Charles University in Prague, Faculty of Medicine and University Hospital, Hradec Kralove, Czech Republic.
700    1_
$a Fekete, Sona $u Institute of Clinical Biochemistry and Diagnostics, Charles University in Prague, Faculty of Medicine and University Hospital, Hradec Kralove, Czech Republic.
700    1_
$a Zimcikova, Eva $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Czech Republic.
700    1_
$a Malakova, Jana $u Institute of Clinical Biochemistry and Diagnostics, Charles University in Prague, Faculty of Medicine and University Hospital, Hradec Kralove, Czech Republic.
700    1_
$a Zivna, Helena $u Radioisotope Laboratories and Vivarium, Faculty of Medicine, Hradec Kralove, Czech Republic.
700    1_
$a Pavlikova, Ladislava $u Institute of Clinical Biochemistry and Diagnostics, Charles University in Prague, Faculty of Medicine and University Hospital, Hradec Kralove, Czech Republic.
700    1_
$a Palicka, Vladimir $u Institute of Clinical Biochemistry and Diagnostics, Charles University in Prague, Faculty of Medicine and University Hospital, Hradec Kralove, Czech Republic.
773    0_
$w MED00001641 $t European journal of pharmacology $x 1879-0712 $g Roč. 824, č. - (2018), s. 115-119
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29428468 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181024152822 $b ABA008
999    __
$a ok $b bmc $g 1339425 $s 1030317
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 824 $c - $d 115-119 $e 20180208 $i 1879-0712 $m European journal of pharmacology $n Eur J Pharmacol $x MED00001641
LZP    __
$a Pubmed-20181008

Find record

Citation metrics

Archiving options